Fear today
- 52 weeks
- 153.58 dollars
▼
218.66 dollars
- Profit
- 3.12 %
- P/E ratio.
- 87.49
- The target price
- $ 211.45
Abbvie Inc. Nyse: abbv It is circulated near its highest levels after the company announced a license agreement with Gubra, a Danish company. The agreement is related to the trial of weight loss, which is in the first stage experience.
Abbvie Gubra paid a payment of $ 350 million for the right to the experimental weight loss drug, GUB014295, which is in the first stage experience. ABBVIE committed to paying Gubra to $ 1.9 billion on the basis of some of the features of development and sales that are fulfilled.
But this step is higher after this advertisement just continues in the bullish style in place with ABBV Stock, which has risen more than 19 % since the beginning of the year. Analyst feelings suggest that the arrow still has a space for a higher operation.
How Jobra differs from the current competition
Entering the weight loss market is logical for ABBVIE when you think that analysts believe that the weight loss market may be $ 130 billion by 2030. NYSE: NVO With Ozmpic and Eli Lilly and Co. New York: Li With Zepbound they are the main players. And such two medicines, GUB014295 (also known as Gubamy) is an injection drug.
But it is important to note that GUBAMY offers a clear difference that Gubra believes will be an advantage. Both OzemPIC and Zepbound targets the hormone GLP-1. On the contrary, Gubamy works as if it is the hormone amylan in the body.
Equiline was identified as a possible therapeutic target to treat obesity. The hormone gives patient brains a feeling of fullness that helps to suppress appetite, reduce eating, and delay the emptying of the stomach. Optimism is that GUBAMY may provide a long -lasting solution for weight management. In the results of the six -week GUBRA study in 2024, patients have achieved 3 % weight loss after one dose.
It is not the one who sells, it is he who buys
In February, Abbvie Insider traded on Marketbeat, three of the different executives ABBVIE, the company’s shares in February. Often retailers are of great importance when the company’s informed sells stocks. In this case, each trade was implemented according to the 10b5-1 base plan.
Al Qaeda 10B5-1 Plan is a written agreement between one of those familiar with companies and the mediator, which sets pre-defined trading instructions at a pre-specified share price, amount and date of treatment. In each case, these plans were placed in November 2024.
It is a good reminder that investors, even those familiar with companies, sell stocks for a variety of reasons. But there is usually only one reason they buy. In the past 12 months, six different members of Congress bought ABBV shares. As investors know, Congress trading does not have the same oversight as the 10B5-1 Qaid Plan when it comes to potential internal trading.
Analysts raise their price goals
Abbvie profit distribution payments
- Profit
- 3.12 %
- Annual profit distributions
- 6.56 dollars
- Record of profit distributions
- 53 years old
- An annual profit growth for 3 years
- 6.04 %
- The percentage of profit distribution
- 273.33 %
- Pay the following profits
- maybe. 15
ABBV profit history
Since the announcement in early March, Abbvie Stock has reached the highest level ever with more than $ 216 per share. The stock fell to about 212 dollars to this writing, and some investors are concerned about the percentage of twelve months (P/E), which is 88X.
However, the ABBVIE P/E striker is only about 17x, which is just less than average for a period of ten years for the company about 20x. This indicates that instead of being expensive, ABV’s shares may be traded with a discount on the historical average and the average arrows in the pharmaceutical and medical sector.
It seems that the consensus of the analysts. Since announcing the deal with Jobra, two analysts, Bank of America and Wales Fargo, raised the targets of their price on ABBV shares to $ 223 and $ 240, respectively. Erste Group Bank upgraded the stock to a strong purchase.
Investors who are looking to participate in knowing whether other analysts will want their expectations before ABBIE offers profits in April. Even if you feel that the stocks are very expensive, you may want to think about starting a job simply to collect the company’s profits, which currently pays $ 6.56 per share annually.
Before you think about Abbvie, you will want to hear this.
Marketbeat follows the best research analyst at Wall Street, the best performance in Wall Street and the stocks they recommend to their customers on a daily basis. Marketbeat has selected the five shares whose senior analysts whispered quietly to their customers to buy now before wiping the broader market … and ABBIE was not in the list.
While ABBIEE currently has a moderate purchase classification between analysts, analysts from the top rankings believe that these five stocks buy better.
Show the five stocks here
Discover the 10 best shares in the Spring of 2025, which were carefully chosen for their growth capabilities amid market fluctuations. This exclusive report highlights the best companies that prepare for prosperity in unconfirmed economic conditions – download now for an investment feature.
